FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318599239> ?p ?o ?g. }

• W4318599239 endingPage "1991" @default.
• W4318599239 startingPage "1985" @default.
• W4318599239 abstract "BACKGROUND The Cancer and Leukemia Group B (CALGB) conducted sequential Phase II multicenter trials to evaluate the activity of edatrexate alone (E) or with leucovorin rescue (EL) in patients with malignant pleural mesothelioma (CALGB Protocol 9131). METHODS Twenty patients were accrued to the E portion of the study and received edatrexate, 80 mg/m2, intravenously over 20–30 minutes weekly. After a protocol amendment precipitated by excessive toxic events with E, 40 patients were enrolled in the EL arm and received the same dose of edatrexate with leucovorin, 15 mg orally, every 6 hours for 4 doses beginning 24 hours after edatrexate. Eligibility criteria included a CALGB performance status of 0–2 and no prior chemotherapy. A central pathology review was performed. Of the 58 patients included in this analysis (20 receiving E and 38 receiving EL), 36 had epithelial cell type and 22 had mixed or sarcomatous cell types. There were 31 patients with measurable disease and 27 with evaluable disease. RESULTS The overall response rate was 25% for E (95% confidence interval [95% CI], 9–49%) and 16% for EL (95% CI, 6–31%). There was a 5% complete response [CR] rate, a 10% partial response [PR] rate, and a 10% regression [R] rate for E and a 0% CR rate, a 3% PR rate, and a 13% R rate for EL. The median survival duration from study entry was 9.6 months and 6.6 months, respectively, for E and EL; 1-year survival was 50% and 32%, respectively, for E and EL. There were four early deaths with the E regimen (including two from neutropenic sepsis) and one early death with the EL regimen (from progressive disease). Principal toxicities included mu cositis, myelosuppression, and rash, which were less frequent with leucovorin rescue. CONCLUSIONS Moderate antitumor activity has been observed with both regimens. Leucovorin rescue ameliorated the mucosal, hematologic, and dermatologic toxicities of edatrexate, but also may have reduced its efficacy. Cancer 1999;86:1985–91. © 1999 American Cancer Society." @default.
• W4318599239 created "2023-01-31" @default.
• W4318599239 creator A5011590188 @default.
• W4318599239 creator A5015680000 @default.
• W4318599239 creator A5048289706 @default.
• W4318599239 creator A5059219836 @default.
• W4318599239 creator A5075108469 @default.
• W4318599239 creator A5090156519 @default.
• W4318599239 date "1999-11-15" @default.
• W4318599239 modified "2023-10-01" @default.
• W4318599239 title "Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma" @default.
• W4318599239 cites W1517335907 @default.
• W4318599239 cites W1948574410 @default.
• W4318599239 cites W1966381243 @default.
• W4318599239 cites W2024386750 @default.
• W4318599239 cites W2028701020 @default.
• W4318599239 cites W2029409133 @default.
• W4318599239 cites W2034326288 @default.
• W4318599239 cites W2055080562 @default.
• W4318599239 cites W2057750354 @default.
• W4318599239 cites W2064189567 @default.
• W4318599239 cites W2077248800 @default.
• W4318599239 cites W2112345476 @default.
• W4318599239 cites W2163176419 @default.
• W4318599239 cites W2181513475 @default.
• W4318599239 cites W2242746637 @default.
• W4318599239 cites W2245589324 @default.
• W4318599239 cites W4245078462 @default.
• W4318599239 cites W4250098627 @default.
• W4318599239 cites W4293241248 @default.
• W4318599239 cites W4375939011 @default.
• W4318599239 doi "https://doi.org/10.1002/(sici)1097-0142(19991115)86:10<1985::aid-cncr15>3.0.co;2-h" @default.
• W4318599239 hasPublicationYear "1999" @default.
• W4318599239 type Work @default.
• W4318599239 citedByCount "36" @default.
• W4318599239 countsByYear W43185992392012 @default.
• W4318599239 countsByYear W43185992392017 @default.
• W4318599239 crossrefType "journal-article" @default.
• W4318599239 hasAuthorship W4318599239A5011590188 @default.
• W4318599239 hasAuthorship W4318599239A5015680000 @default.
• W4318599239 hasAuthorship W4318599239A5048289706 @default.
• W4318599239 hasAuthorship W4318599239A5059219836 @default.
• W4318599239 hasAuthorship W4318599239A5075108469 @default.
• W4318599239 hasAuthorship W4318599239A5090156519 @default.
• W4318599239 hasBestOaLocation W43185992391 @default.
• W4318599239 hasConcept C126322002 @default.
• W4318599239 hasConcept C141071460 @default.
• W4318599239 hasConcept C142724271 @default.
• W4318599239 hasConcept C2776283816 @default.
• W4318599239 hasConcept C2776694085 @default.
• W4318599239 hasConcept C2777407522 @default.
• W4318599239 hasConcept C2778822529 @default.
• W4318599239 hasConcept C71924100 @default.
• W4318599239 hasConcept C90924648 @default.
• W4318599239 hasConceptScore W4318599239C126322002 @default.
• W4318599239 hasConceptScore W4318599239C141071460 @default.
• W4318599239 hasConceptScore W4318599239C142724271 @default.
• W4318599239 hasConceptScore W4318599239C2776283816 @default.
• W4318599239 hasConceptScore W4318599239C2776694085 @default.
• W4318599239 hasConceptScore W4318599239C2777407522 @default.
• W4318599239 hasConceptScore W4318599239C2778822529 @default.
• W4318599239 hasConceptScore W4318599239C71924100 @default.
• W4318599239 hasConceptScore W4318599239C90924648 @default.
• W4318599239 hasIssue "10" @default.
• W4318599239 hasLocation W43185992391 @default.
• W4318599239 hasOpenAccess W4318599239 @default.
• W4318599239 hasPrimaryLocation W43185992391 @default.
• W4318599239 hasRelatedWork W2003938723 @default.
• W4318599239 hasRelatedWork W2047967234 @default.
• W4318599239 hasRelatedWork W2118496982 @default.
• W4318599239 hasRelatedWork W2308048091 @default.
• W4318599239 hasRelatedWork W2364998975 @default.
• W4318599239 hasRelatedWork W2381291530 @default.
• W4318599239 hasRelatedWork W2439875401 @default.
• W4318599239 hasRelatedWork W4238867864 @default.
• W4318599239 hasRelatedWork W4385577036 @default.
• W4318599239 hasRelatedWork W2525756941 @default.
• W4318599239 hasVolume "86" @default.
• W4318599239 isParatext "false" @default.
• W4318599239 isRetracted "false" @default.
• W4318599239 workType "article" @default.